The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)
Official Title: A Phase III, Randomized, Double-blind Study of Chemotherapy With Daunorubicin or Idarubicin and Cytarabine for Induction and Intermediate Dose Cytarabine for Consolidation Plus Midostaurin (PKC412) or Chemotherapy Plus Placebo in Newly Diagnosed Patients With FLT-3 Mutation Negative Acute Myeloid Leukemia (AML)
Study ID: NCT03512197
Brief Summary: The purpose of this study was to confirm the preliminary evidence from early clinical trials that midostaurin may provide clinical benefit not only to AML patients with the FLT3-mutations but also in FLT3-MN (SR\<0.05) AML (FLT3 mutant to wild type signal ratio below the 0.05 clinical cut-off). This study evaluated the efficacy and safety of midostaurin in combination with daunorubicin or idarubicin and cytarabine for induction and intermediate-dose cytarabine for consolidation, and midostaurin single agent post-consolidation therapy in newly diagnosed patients with FLT3-MN (SR\<0.05) AML.
Detailed Description: This was a multi-center, multinational, randomized, double-blind Phase III study using a group sequential design. Subjects were stratified according to age (\<60 vs. ≥ 60 years). Subjects within each stratum were randomized in a 1:1 ratio into one of two treatment arms: Midostaurin + chemotherapy 'or' Placebo + chemotherapy. The study consisted of the following phases: Screening/randomization phase: Subjects had to sign informed consent form before screening for enrollment. Subjects started chemotherapy at day 1 and were randomized at day 8. Induction phase: All subjects received at least one cycle (28 days) of induction therapy with continuous infusion cytarabine (D1 - D7) and daunorubicin or idarubicin (D1 - D3) (induction 1). Subjects who did not achieve CR or CRi with adequate blood count recovery after Induction 1 received a second cycle with intermediate-dose cytarabine (D1 - D3) and daunorubicin or idarubicin (D1 - D3) (induction 2). Subjects who did not achieve CR or CRi with adequate blood recovery after induction 2 discontinued study treatment and were followed for survival. Consolidation phase: Subjects who achieved CR or CRi with adequate blood count recovery after induction with one or two cycles of induction proceeded to consolidation therapy with either 3 or 4 cycles respectively of intermediate-dose cytarabine (D1 - D3), or to Hematopoietic Stem Cells Transplantation (HSCT) with or without preceding consolidation cycles. Post-consolidation phase: Subjects who maintained CR or CRi with adequate blood count recovery at the end of the consolidation phase received 12 cycles (28 days/cycle) of continuous therapy with midostaurin or placebo twice daily at 50 mg. Subjects who underwent HSCT after achieving CR or CRi with adequate blood count recovery received midostaurin or placebo twice daily 50 mg post-transplant therapy, continuously, for up to 12 cycles (28 days/cycle). Post HSCT post-consolidation therapy began \>30 days but not later than 100 days following HSCT. Follow-up phase: All enrolled subjects were followed through the treatment period and until relapse/treatment failure, thereafter for start of new line of therapy and survival.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
University of Chicago Medical Center ., Chicago, Illinois, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Oregon Health and Science Univ, Portland, Oregon, United States
Novartis Investigative Site, Caba, Buenos Aires, Argentina
Novartis Investigative Site, Westmead, New South Wales, Australia
Novartis Investigative Site, Woolloongabba, Queensland, Australia
Novartis Investigative Site, Prahran, Victoria, Australia
Novartis Investigative Site, Murdoch, Western Australia, Australia
Novartis Investigative Site, Linz, , Austria
Novartis Investigative Site, Vienna, , Austria
Novartis Investigative Site, Wien, , Austria
Novartis Investigative Site, Antwerpen, , Belgium
Novartis Investigative Site, Brugge, , Belgium
Novartis Investigative Site, Roeselare, , Belgium
Novartis Investigative Site, Porto Alegre, RS, Brazil
Novartis Investigative Site, Sao Paulo, SP, Brazil
Novartis Investigative Site, Sao Paulo, , Brazil
Novartis Investigative Site, Sofia, , Bulgaria
Novartis Investigative Site, Brno - Bohunice, , Czechia
Novartis Investigative Site, Plzen-Bory, , Czechia
Novartis Investigative Site, Bayonne, Bayonne Cedex, France
Novartis Investigative Site, Angers Cedex 1, , France
Novartis Investigative Site, Avignon, , France
Novartis Investigative Site, Dijon, , France
Novartis Investigative Site, Lille Cedex, , France
Novartis Investigative Site, Nantes Cedex 1, , France
Novartis Investigative Site, Paris, , France
Novartis Investigative Site, Pierre Benite, , France
Novartis Investigative Site, Toulouse, , France
Novartis Investigative Site, Regensburg, Bavaria, Germany
Novartis Investigative Site, Schwerin, Brandenburg, Germany
Novartis Investigative Site, Bad Saarow, , Germany
Novartis Investigative Site, Berlin, , Germany
Novartis Investigative Site, Berlin, , Germany
Novartis Investigative Site, Berlin, , Germany
Novartis Investigative Site, Berlin, , Germany
Novartis Investigative Site, Bochum, , Germany
Novartis Investigative Site, Bonn, , Germany
Novartis Investigative Site, Braunschweig, , Germany
Novartis Investigative Site, Darmstadt, , Germany
Novartis Investigative Site, Duesseldorf, , Germany
Novartis Investigative Site, Duisburg, , Germany
Novartis Investigative Site, Eschweiler, , Germany
Novartis Investigative Site, Essen Werden, , Germany
Novartis Investigative Site, Flensburg, , Germany
Novartis Investigative Site, Giessen, , Germany
Novartis Investigative Site, Gottingen, , Germany
Novartis Investigative Site, Hamburg, , Germany
Novartis Investigative Site, Hamburg, , Germany
Novartis Investigative Site, Hannover, , Germany
Novartis Investigative Site, Homburg, , Germany
Novartis Investigative Site, Karlsruhe, , Germany
Novartis Investigative Site, Kiel, , Germany
Novartis Investigative Site, Leipzig, , Germany
Novartis Investigative Site, Luebeck, , Germany
Novartis Investigative Site, Magdeburg, , Germany
Novartis Investigative Site, Mainz, , Germany
Novartis Investigative Site, Muenchen, , Germany
Novartis Investigative Site, Osnabrueck, , Germany
Novartis Investigative Site, Paderborn, , Germany
Novartis Investigative Site, Rostock, , Germany
Novartis Investigative Site, Siegen, , Germany
Novartis Investigative Site, Stuttgart, , Germany
Novartis Investigative Site, Stuttgart, , Germany
Novartis Investigative Site, Ulm, , Germany
Novartis Investigative Site, Wuerzburg, , Germany
Novartis Investigative Site, Zwickau, , Germany
Novartis Investigative Site, Haifa, , Israel
Novartis Investigative Site, Petach Tikva, , Israel
Novartis Investigative Site, Tel Aviv, , Israel
Novartis Investigative Site, Alessandria, AL, Italy
Novartis Investigative Site, Ancona, AN, Italy
Novartis Investigative Site, Bergamo, BG, Italy
Novartis Investigative Site, Brescia, BS, Italy
Novartis Investigative Site, Catania, CT, Italy
Novartis Investigative Site, Milano, MI, Italy
Novartis Investigative Site, Modena, MO, Italy
Novartis Investigative Site, Palermo, PA, Italy
Novartis Investigative Site, Piacenza, PC, Italy
Novartis Investigative Site, Pescara, PE, Italy
Novartis Investigative Site, Perugia, PG, Italy
Novartis Investigative Site, Reggio Calabria, RC, Italy
Novartis Investigative Site, Roma, RM, Italy
Novartis Investigative Site, Roma, RM, Italy
Novartis Investigative Site, Roma, RM, Italy
Novartis Investigative Site, Taranto, TA, Italy
Novartis Investigative Site, Torino, TO, Italy
Novartis Investigative Site, Vicenza, VI, Italy
Novartis Investigative Site, Nagoya-city, Aichi, Japan
Novartis Investigative Site, Matsuyama-city, Ehime, Japan
Novartis Investigative Site, Fukuoka city, Fukuoka, Japan
Novartis Investigative Site, Fukushima city, Fukushima, Japan
Novartis Investigative Site, Gifu shi, Gifu, Japan
Novartis Investigative Site, Fukuyama, Hiroshima, Japan
Novartis Investigative Site, Tsukuba city, Ibaraki, Japan
Novartis Investigative Site, Isehara, Kanagawa, Japan
Novartis Investigative Site, Nagasaki-city, Nagasaki, Japan
Novartis Investigative Site, Okayama city, Okayama, Japan
Novartis Investigative Site, Hirakata-city, Osaka, Japan
Novartis Investigative Site, Osaka Sayama, Osaka, Japan
Novartis Investigative Site, Hamamatsu, Shizuoka, Japan
Novartis Investigative Site, Shimotsuke, Tochigi, Japan
Novartis Investigative Site, Bunkyo ku, Tokyo, Japan
Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan
Novartis Investigative Site, Aomori, , Japan
Novartis Investigative Site, Kyoto, , Japan
Novartis Investigative Site, Osaka, , Japan
Novartis Investigative Site, Yamagata, , Japan
Novartis Investigative Site, Bergen, , Norway
Novartis Investigative Site, Oslo, , Norway
Novartis Investigative Site, Gdansk, , Poland
Novartis Investigative Site, Lisboa, , Portugal
Novartis Investigative Site, Porto, , Portugal
Novartis Investigative Site, Cordoba, Andalucia, Spain
Novartis Investigative Site, Sevilla, Andalucia, Spain
Novartis Investigative Site, Salamanca, Castilla Y Leon, Spain
Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain
Novartis Investigative Site, Caceres, Extremadura, Spain
Novartis Investigative Site, Barakaldo, Pais Vasco, Spain
Novartis Investigative Site, Barcelona, , Spain
Novartis Investigative Site, Madrid, , Spain
Novartis Investigative Site, Madrid, , Spain
Novartis Investigative Site, Valencia, , Spain
Novartis Investigative Site, Zaragoza, , Spain
Novartis Investigative Site, Bern, , Switzerland
Novartis Investigative Site, Zurich, , Switzerland
Novartis Investigative Site, Putzu City, Chiayi Hsien, Taiwan
Novartis Investigative Site, Kuei Shan Chiang, Taoyuan Taiwan ROC, Taiwan
Novartis Investigative Site, Kaohsiung City, , Taiwan
Novartis Investigative Site, Taipei, , Taiwan
Novartis Investigative Site, Adana, , Turkey
Novartis Investigative Site, Ankara, , Turkey
Novartis Investigative Site, Aydin, , Turkey
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR